Were the WHO-recommended Human Influenza Vaccine Formulations Appropriate for Kenya During the 2010-2011 Season? Inferences from the HA1 Gene Analysis

Authors

  • Wallace D. Bulimo
  • Silvanos Mukunzi
  • Rachel Achilla
  • Benjamin H. Opot
  • Finley Osuna
  • Janet Majanja
  • Meshack Wadegu US Army Medical Research Unit, Kenya , Kenya Medical Research Institute image/svg+xml
  • Eyako K. Wurapa

Keywords:

Influenza vaccine formulations, HA1 gene, Kenya

Abstract

Influenza is an acute respiratory illness that spreads across the world in annual epidemics and occasional pandemics (WHO, 2003). In annual epidemics, the disease infects about 5 - 15% of the human population with an estimated 3-5 million severe disease cases and 250,000 - 500000 deaths (Lin et al, 2004). Influenza A and B viruses are the main causative agents of the disease (Baras et al, 2008). Type A influenza viruses are further classified into subtypes based on antigenic properties of surface glycoproteins, hemagglutinin (HA), and neuraminidase (NA). Only a limited number of subtypes have been associated with infections in humans (Baras et al, 2008). Since 1977, subtypes H1N1 and H3N2 viruses have widely cocirculated in the human population (Wang et al, 2009).

References

Downloads

Published

2012-07-03

Similar Articles

31-40 of 62

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)